135 related articles for article (PubMed ID: 25202052)
1. Serum EpCAM expression in pancreatic cancer.
Gebauer F; Struck L; Tachezy M; Vashist Y; Wicklein D; Schumacher U; Izbicki JR; Bockhorn M
Anticancer Res; 2014 Sep; 34(9):4741-6. PubMed ID: 25202052
[TBL] [Abstract][Full Text] [Related]
2. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sergeant G; Roskams T; van Pelt J; Houtmeyers F; Aerts R; Topal B
BMC Cancer; 2011 Jan; 11():47. PubMed ID: 21281486
[TBL] [Abstract][Full Text] [Related]
3. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
5. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
6. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
[TBL] [Abstract][Full Text] [Related]
7. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
[TBL] [Abstract][Full Text] [Related]
9. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
11. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma.
Ren YQ; Zhang HY; Su T; Wang XH; Zhang L
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3063-8. PubMed ID: 25392106
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
[TBL] [Abstract][Full Text] [Related]
14. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
15. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
16. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay.
Liberati D; Marzinotto I; Brigatti C; Dugnani E; Pasquale V; Reni M; Balzano G; Falconi M; Piemonti L; Lampasona V
Cancer Biomark; 2018; 22(2):351-357. PubMed ID: 29660901
[TBL] [Abstract][Full Text] [Related]
17. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer.
Felix K; Hinz U; Dobiasch S; Hackert T; Bergmann F; Neumüller M; Gronowitz S; Bergqvist M; Strobel O
Pancreas; 2018 Jan; 47(1):72-79. PubMed ID: 29189449
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer.
Karabulut S; Tas F; Tastekin D; Karabulut M; Yasasever CT; Ciftci R; Güveli M; Fayda M; Vatansever S; Serilmez M; Disci R; Aydıner A
Tumour Biol; 2014 Sep; 35(9):8849-60. PubMed ID: 24891186
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma.
Waragai Y; Suzuki R; Takagi T; Sugimoto M; Asama H; Watanabe K; Kikuchi H; Hikichi T; Masamune A; Kang Y; Fleming JB; Ohira H
Pancreatology; 2016; 16(6):1044-1050. PubMed ID: 27665173
[TBL] [Abstract][Full Text] [Related]
20. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]